Earnings call transcript Q4 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Viridian Therapeutics Fourth Quarter and Full Year 2022 Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the floor over to Ms. Louisa Stone, Manager of Investor Relations at Viridian. Please go ahead.

Louisa Stone

everyone, call. fourth welcome, year and and conference XXXX you, to quarter our full Thank release our at press page The reporting of the available our Investors on corporate website www.viridiantherapeutics.com. financial results is

President, this Relations. Strategy Joining me and Executive James, Officer; Rajagopalan, Business and Kristian Officer; our are and Vice Myers, our Financial Dr. our Todd Chief Chief morning Corporate Humer, Officer; on Investor President Scott Chief Affairs call and the Deepa Product Senior and

description remind to our everyone this we risks addition begin, cause with These like Before contain commercialization be that could regarding can and recent materially found actual would and statements in call statements to our to differ XX-Q SEC. and uncertainties will activities. financial that file webcast these forecasted. and development I conference on of in and research plans XX-K are regulatory, most risks forward-looking to product outlook, subject A Form the results from those

now like I CEO. over Myers, and to Scott call would President our turn the to

Scott Myers

Good quarterly morning, first us This joining today. everyone. about for month Thanks my Louisa. joining ago. call is a since conference you, Viridian Thank

recently, experience and public UCB. served a four from as Most few those of and familiar background, spent pharmaceutical roles in I've with also member Boards XX a biopharmaceutical I abroad and Aerocrine. Johnson Cascadian are who and I've for my the & have of space. and years companies. held my and AMAG, the Johnson in Earlier technology senior commercial you over medical in Rainier, CEO For I not at career, private Board companies: Chairman the U.S.

looking TED colleagues. Viridian, deeper learning CEO for further Company's preclinical forward more in our ways my look appointment execution. development resolve and many met excitement processes Over our on data about time diving previous to into the our the past spent have with as plans I building and which improve at all of and and my and exciting company. plans research, I have our strengthened since have for I months to new

in and a class We medicines research with opportunity expand IV and efforts our administered TED. to TED beyond significant to bring have best development of patients front and in potential subcutaneous us

has team support efforts. late-stage been growing areas key Our our to rapidly in development

focused are operational lead to We to organization. fully across and excited as building adding a into the company. support we of teams our on to right together support resources integrated I'm work our biopharmaceutical execution vision Viridian achieve the

review we will XXXX. I'll results, Viridian discuss to CFO, and Now, questions. taking financial the Kristian in progress important Humer, made our our then that look forward your

receptor was program, factor-X XXXX VRDN-XXX, TED our IGF-XR. antibody growth IV believed full across form, to antagonist year a humanized of lead our insulin-like especially programs, a for monoclonal the as in an act impactful or

this we've efficacy Over active of the cohorts X/X of stream dose and steady VRDN-XXX three with clinical safety positive clinical past quarters, the TED. Phase evaluating several the top from trial patients line announced in of data ongoing

that showing we of this third significant cohort VRDN-XXX, TED. mg/kg showed In infusions X reported early improvements patients from top rapid data low just both after of the year, line dose symptoms and in two signs January of and

to efficacy with XXXX which prior in with name is only belief results and reported brand XX differentiated the TED. drug FDA of treat marketed offer and patients approved reinforce XX may we mg/kg a safety teprotumumab the VRDN-XXX TEPEZZA, similar combined data to mg/kg early that relative under This our the profile

patients regarding IV data will of concept with TED. evaluating we the study program will proof provide set The the results from next in initial be VRDN-XXX the VRDN-XXX chronic

quarter of in these report results the to expect second year. this We

we ongoing global initiated our positive in from trials in trial which data The to the of with the safety XXXX support X trials. Phase VRDN-XXX active X X TED. of ongoing efficacy patients and moving December to our evaluate Now THRIVE plan and Phase Phase

that first treatment TED. toward for in a in results on and proud enrolled the a for The to potentially We patient the with line providing were with was option Viridian announce new trial patients middle expected of a and improved study, top major remains track meaningful step milestone XXXX.

of upcoming with the THRIVE-X Phase of to we patients expected topline Phase Following known a XXXX. middle results data in as TED, X with the XXXX the second trial at start in plan chronic end X

device programs reduce patients candidates pen I'll the and which turn VRDN-XXX of friendly, TED. All from VRDN-XXX. could subcutaneous suffering convenient, subcutaneous potential patient have include VRDN-XXX, burden be significantly the into a now to three for which to self-administered our developed care

The supports candidate. potential its subcutaneous is recent program dose low a data of VRDN-XXX

now as a are partial antagonist results planning healthy our in quarter a volunteers XX IGF-XR. We year. in volunteers trial healthy in VRDN-XXX act X VRDN-XXX XX days technology, antibody compared this fourth This XX X Phase incorporates expected led is monoclonal of antibody half-life Phase to in teprotumumab. of to the days believed which for novel with our to to half-life and a up of trial to extension

concept currently with in VRDN-XXX TED team the patients by to Our is active of planning a year. trial proof with data this end of evaluate expected

of same addition is VRDN-XXX. for is that except antibody as half-life acid VRDN-XXX the technology IGF-XR sequence amino anti the an the monoclonal in extension incorporated with VRDN-XXX

VRDN-XXX X investigational fourth the quarter quickly second application of quarter drug healthy towards expected new in the advancing results We in in with XXXX. are XXXX, volunteers of an Phase

is program, of we the clinical one program pivotal XXXX. data, lead the our XXXX. planned middle the select subcutaneous Following before candidates for selected of to as the end of trial plan ultimately The lead

at on year's held Florida. to the being NANOS VRDN-XXX American this presentations Meeting of week North that's VRDN-XXX forward Neuro-Ophthalmology Society look in or our and Orlando, Annual next both upcoming We

physician throughout the and amongst year Viridian present The us our patient generate engage team to medical hope the communities. is with community, and targeting to in and awareness medical congresses where data the data further we allowing our about TED

treating activities programs. If significant available can our TED. and have physicians you approved, complete see, patients with development for our our most TED believe we and represent would programs made and As subcutaneous we commercial research intravenous throughout progress in offering the

As differentiated new dosing start be new these convenient the therapies would expect simpler, more market. in with entrants highly regimens, competitive to potentially we

with expand respect is the multiple one advancing this early Please tuned VRDN-XXX beyond TED our at Finally, programs pipeline, rare of intend currently Company preclinical additional on year. as we information programs, these years in VRDN-XXX, autoimmune including to to stay The least we to later into provide coming and VRDN-XXX. stage and diseases. plan preclinical

ending and will to With that, turn Kristian? who Kristian, provide the full review financial XXXX. I year the over for call a fourth will quarter

Kristian Humer

morning, and Thank a like earlier opportunity for refer I'd this detailed year to and take to you our a press items. fourth quarter release Scott. everyone. of Good issued to review the XXXX full results you, summary financial our today for few

investments, We year current of million XXXX. and ended $XX cash credit short-term of million half full that excluding investments XX, cash, million $XXX.X and our sufficient September as quarter fund short-term cash, be cash facility approximately the second with in XXXX. operations with the into equivalents fourth our equivalents are compared $XXX.X and to believe We will

clinical the upfront were of payments, payments, milestones same were XXXX, and costs, personnel by was same $XX.X development Research expenses, was preclinical quarter primarily million and XXXX, $XXX.X for well with fourth expenses Research $XX.X XX, by the million development research million increase XX $XX.X compared trial development for increase preclinical expenses during to and expenses ended in The compared related and costs. and during as in and and the last upfront driven driven year. expenses primarily to increase million costs, December the an related period expenses. as development last research The expenses milestones year. with months CMC period expenses CMC in and

and X, XX.X Series had B stock, stock approximately of stock shares an included and of shares an A of shares of upon XXXX, XX,XXX and preferred XXX,XXX million conversion as-converted March common of basis, Viridian aggregate As approximately of Series the respectively. common of million XX.X shares XX.X million on issuable which outstanding common stock

the With that, operator open I'll Operator? ask to call questions. for the

Operator

now is Instructions]. questions. for open [Operator Thank The you. floor

today The first ahead. ISI. is go from Evercore Gavin of coming question Clark-Gartner Please

Gavin Clark-Gartner

up? Hey, volunteers? for subcu and reason terms XXX test (ph) I'm case proof concept doesn't TED] on welcome, measured can a in XXX Thank us the and backup taking thanks endpoint to just wondering give And then Scott, healthy be you. any difficulty) how the some just time of XXX questions. what reason? out trial in work more details this you for patients the like what [in subcutaneous (technical of might and may in Is the what look the many for this

Scott Myers

Yes.

thanks the question. So, for

in at and know healthy the we us now the we had gives the benefit a one, like more looking having decision mg/kg about immunogenicity lot XXX test and bioavailability first look think year. look just we more make the the can of cohort, to to volunteers it several the a we opportunity end that information in at, have On it I X XXX. just compounds we're of at And to at

one, haven't about program. On the we particular second more any spoken that

Gavin Clark-Gartner

Thanks. it. Got

Scott Myers

Thanks welcome. the for You're question.

Operator

Thank from Securities. ahead. Please is question Smith go you. coming The next Thomas SVB of

Unidentified Analyst

our shape on study? questions. And competitor (ph) own your follow-up, then data in chronic efficacy This from strategy the a And active taking TED expect help your just results these proof you do of expected could your thinking Thanks about versus expectations for for is how the TED? patients? chronic to everyone. concept development for clinical Can Hi, in Yes. TED look just you how as Tom. [Mike] your discuss

Scott Myers

one. on I'll those So first unpack questions the several

see so. chronic level be one it a millimeters that. to proptosis, negative Given don't to want We some in but giving certainly on growing doses or we like overshoot of impact doses, two two the may

and come they're about a to data course out Horizon’s therapy. expect of mid-year full We using

might be higher. there’s So,

back been are got there I with XX odd patients about treated at reports TEPEZZA, actually case where they out that pretty look good you the think results. have in looked we some chronic there's and If at,

want we the So be to data in all, compelling. all

So so to use the the we and final it. helpful. people all when can covered second of and of repeat and And could go if you we question, get companies can with would a a get lot noise get we be that make that can that access can approval us third insurance

Unidentified Analyst

Sure.

bit? of of, about to thinking TED? through then efficacy could it competitor a terms clinical versus you I help data strategy how of patients little expect these all, the development chronic in first TED in And that the kind your shape walk look Just in know mentioned you how you patients? just your active

Scott Myers

Yes, we the definitely. it's -- disease, the If know the numbers as high. plateau phase of as level a are they when usually level not quite chronic in biphasic out disease,

active effect you the happen. won't total And so seeing like probably see would an

CAS, with and lower you off start off proptosis. start lower You potentially with

talk diplopia to a like all not magnitude active. the look then scores effective relief proptosis to quicker. the at you So the onset see we is and it's may and totality we reduce CAS, to -- and about see of whether of have proptosis. of What And the we'll rapid

And to they hopefully and of their decisions and will we'll their data competition, with to regard -- help and our data study going to but what have on to their us see us, look the that's some own we're the forward. going before this going looks like scheme guide release information data I at make

Unidentified Analyst

very Thanks Great. much.

Scott Myers

welcome. for your question. you Thank You're

Operator

question ahead. coming Thank of go Busyoti is next [ph]. from you. The Cam Please Jefferies

Unidentified Analyst

have assets morning. selection Could Thank And of subcutaneous for volunteer for for second you will cohort you'll given then while kind dose healthy how that XXX data chronic the the the year? you. rationale like X TED between the milligrams? at team, select by have three XXX you'll maybe end of your Phase results Hi, discuss some you for

Scott Myers

Yes.

were results ranging we try the is steady again XX patients in cohort that in all dose X this These the state one, previous We in On wanted cohorts, January, our first study. mg/kg X to testing be such we done good mg/kg. the tend to in and we’ve question a saw some at mg/kg it both asked.

the data as of such multitude data good a question, if it's our it bioavailability, low to us programs better earlier also subcu the volunteer because as selection I to our understand didn’t that guide So always to the and data healthy to in health, going as continues on use well we're I at definitely program. to a make inform lower such on work, immunogenicity. will mentioned, could And -- see dosage. we Obviously, think dose an see subcutaneous

data that give And we will then and well, lined better the us all seen choice we've once it a get -- make. to can up really

Unidentified Analyst

did too? to antibody Excellent. maybe follow a options assets? with are the for And one where maybe that XXX attractive limited going out kind could creative what kind your you is some optimization the disease you. as or competition markets Thank roadmap do follow-up, in there some of you of you same non Are more some for rare market TED pursuing there

Scott Myers

there's a a antagonist we markets partial that's we've potential or it's for but good full seen that believe you the convenience and Viridian. it's not an drug we perfect entrant, even entrant Yes, safety early beneficial of there's a we're look great be a a great question. of with or going as its, on because unmet fixed can differentiate been based efficacy to on Really of delivery. lot very maybe of antagonist, maybe teprotumumab, hallmark We needs, and

can development market bring where commercialization efforts differentiate access rapid things. competition. point, also our of use and there's to feel limited to that by bear through we going then market. we and and will our like those all market we're So those type completely engineering, to We a And to pick analysis build good

So we year. to at focus TED, look least it's out unveiling right coming -- now preclinical really is our this programs of but the forward one

Unidentified Analyst

Thank so much. Awesome. you

Scott Myers

Thank question. you for welcome. You're the

Operator

Thank of Securities. Chico Wedbush Laura question is coming ahead. from go you. The next Please

Laura Chico

question little a Scott, program opportunity very were guys. most much to of that you excited if you to love for I a you, and with as taking then what stands about one morning Viridian And the would respect the for Kristian. to one more there's question. most about Good out perhaps compelling? follow-up hear for Thanks bit

very expense more runway and cash guidance to could the you to operating in the think to rate exiting Just quarter? the bit the in wondering about just Thanks of trying a ’XX much little seeing spend speak we're relative pace guys. if fourth

Scott Myers

question. the for thanks No, Yes.

multiple So, I company. I the was I by concept but things. really did pitched excited was leader of the a of -- becoming

our both programs First pipeline that. when pipeline going behind have you subcu at look we of chart, and and number foremost, a the IV in then and

bit I about the rare XXX just I but smaller think with say a clinical going not companies, necessarily we're that's programs on. would is cap, although in in market people smaller Company multiple

directly we're part of My in UCB you history has and little there's could countries and both from oral, is to an of a analog we J&J to market, I but where -- first less similarities to the what how analog businesses were a the market that Europe launch where over of anti-TNF that at been look doing you between J&J, anti-TNF, CIMZIA, was which the as think the my at go even IV and subcu maybe a time. TED I lot and actually evolve and

and assets, have these rough well look their met – horsepower well-capitalized of commitment very it's finally, lot us I lot to in. forward investors integrated. the early-stage a excited of move be an the done about and four to assets -- assets company even independent really and they our do of Board impressed couple of to and intellectual a of commitment it's company a to their fully then companies willingness years late-stage And the you I'm team for can biotech mean, I've want the and with I find the and I and it as XX companies, middle-stage And here. across years be that's as at that to areas. And who's that company. in what build thrill sort you been a

Kristian Humer

Laura. you, Thank

$XXX So end million of of in we cash Laura, terms cash had XXXX. the in guidance, around at

XXXX and of on runway, readouts bit at it both second program XXXX. the of program a end THRIVE-X data into runway terms funds a is little into In cash half of and by that basis, THRIVE XXXX,

bake-off at into funded subcu move where one end decision select Our point programs XXXX. what we to trial, are programs kind pivotal of call our forward we a of through the to subcu of the

from pivotal trial selecting so to funded we program prep is a that swiftly pivotal Importantly, move trial. the can

will XXXX. gotten of has We course unveil

let these the All funded. of the funded filing programs, be IND how these are can we'll programs we selection, unveil once and through either market programs decide candidate

those expenses, as should terms operating increase. of to move closer assume In expenses commercialization we you will that

commercialization, terms kind up pivotal R&D being to a As in subcu trial to program. we closer increase that up expenses for and will of also ramp of our move ready and as we with gear

Laura Chico

guys. Thank Very you. helpful

Kristian Humer

you, Thank Laura.

Operator

Thank Securities. of go question Butler Jason The from JMP Please you. next coming ahead. is

Jason Butler

add joining. a the for your you us thanks you the device on where into potential incorporate taking Scott, Wondering you're Hi, And question. go-to-market device? congrats you let my when could pen at the think give clinical me with on Thanks. program? update if an subcu can

Scott Myers

to – effort. I'm and that that she's here, her. pitch actually, overseeing going is to one I'm Deepa

Deepa Rajagopalan

question. for the Scott. Thanks Thanks,

of are studies auto-injector of subcu that move year. in looking our assessing those off look forward integrating and number following we program to program. subcu patient selecting we at we stages into We're the as options, our later devices and it subcu early a So device into support to bake this

Jason Butler

Thanks. Okay.

Scott Myers

Jason. you, Thank

Operator

The of Thank from you. Sam question LifeSci next Capital. is Slutsky coming

Sam Slutsky

Good Thanks for taking morning is on Ami. for question. Sam This the everyone.

us can And Just just of IV criteria to of Phase TEPEZZA? on ongoing enrolled? how inclusion the the study, patients compares chronic the remind being TED study you of that then

Scott Myers

Yes.

the chronic Proptosis, onset the zero of than months, on even. study believe months. the criteria TED millimeters, of chronic I equal zero a that than from one. XX to it's So, symptoms to study, ranges inclusion is and XX for than CAS greater TEPEZZA greater or X are CAS greater or

Deepa Rajagopalan

times years. years of diagnosis and XX inclusion two from between to And

Sam Slutsky

Got you.

as interpreting And kind of baselines helpful. guess just do then so That's those and any on suspect we about forth results? I differences Okay. based you think

Scott Myers

particularly. Not

to have see our effect. going works, see we CASs. doses, using probably we're our because lower to how of the have I And to and we'll think expect we're two drug only magnitude

be eight to how we'll dose we think doses, good really two just effect regimen see news. see after their any works. And if that would I have

Sam Slutsky

it. Got

you. Okay. Thank

Scott Myers

Sam. you, Thank

Operator

The Kalpit you. is next of question B. Securities. Riley coming Thank Patel from

Kalpit Patel

kilogram? of same Good disclosed of dosing XXX with one for to the with morning. you're XXX. IV in you as X-milligram taking patients then number it give one the be us of that study, the frequency that per CAS Thanks scores? for for all include initially planned sense the infusions going you formulation? if to Can a will and test questions. And Maybe subcu the Is THRIVE-X formulation the have planning

Scott Myers

the believe identified subcu will be. what we've don't dosing I regimens

So that's been disclosed. not

question? could XXX and repeat you the On on XXX,

Kalpit Patel

that THRIVE-X all the have if patients XXX, disclosed For scores? you of study, include CAS types will with all

Todd James

X, be molecule that to goes currently THRIVE-X, to to decision that albeit being data be equal Hey final see specific would for here. CAS. that II this will have make to chronic tend on X, being XXX Xs patients active to it wait to We'll and the protocol inclusive on to Todd than proof-of-concept the within patients and X. a is ahead expect design or Phase Xs relative all greater is design to our CAS, inclusive of and we current mirror it how

Kalpit Patel

XXX Okay. THRIVE-X. Yes, I meant for for

Scott Myers

Thank studying in you. a XXX weren't We that for Thanks we up. chronic. little because clearing were confused

Kalpit Patel

it mixed I Yes. up.

Operator

next H.C. The of from Wainwright. Please Tsao ahead. go Douglas question coming you. Thank is

Douglas Tsao

a potential curious, the two you there different think from contemplated advancing TED active chronic you. for do of Just TED have Thank just of advantages? may sort pricing potentially standpoint, be versus some or strategic value strategic assets you

Scott Myers

putting think marketplace assets very I the would into be two same difficult.

than retrospectively no is looking know used. way because to being protocol think other which I at real there's

eventually see of and be centers used to our it be X-dose a benefit have is I providers think X-dose see same patients, hit in would regimen infusion and unique the if efficacy there a shorter to study, active can doing the quite and which great you a course even therapy. an could because and amounts what we is

great in way the therapeutic patients why to I And and So that's of strategy we that's can And the subcu not go forward, the marvelous that admission it. a so a chronic, possibility. to own think, idea go, take moving control doing we're their that's think certainly home, is then at a have real to caregivers. of

Douglas Tsao

Thanks. Okay.

Scott Myers

the question. for Thanks

Operator

from coming go is Please question Michael Thalmann. of ahead. next The Higgins you. Ladenburg Thank

Michael Higgins

like near-term initial for proof-of-concept Congratulations, couple et A chronic there, you're of as What events Scott, share looking patients, on be XXX should for on in QX. planning TED cetera? to results Thanks. joining questions patients. Viridian how we Looks CEO. many in

Scott Myers

sure. Yes,

XX cohorts. arm and X mgs course there. diplopia like per that's similar will and see basically, see two And TEPEZZA's to can't other be the versus It's we're that both How but the kg. over in doses we after we in our patients effect I this say, only kg proptosis. But be per designs. there'll to to So to effect well. We in per think to actually, XX times and full all spoke eight high mgs trial two this kg about placebo going X since XX Its be QX we're very mgs we some already. an doses expect -- doses, see CAS two like of definitely of as population? collecting scores the really a And

have versus we X is much CAS range Xs. X, a inclusion in to and criteria, So TEPEZZA's, Xs the broader which

those tend there's that So look with a after chronic mentioned, population. see an we the of did were as there, you they TEPEZZA redosing. good on chronic studies and see effect retreated effect but be patients case actually if hope But series and a and I lower TED little a pretty had in to great at, to

which So of of really deal the if the the the closes, behind and and with sense to will ability take second strategy that. we're hoping convince out broaden now that coverage take And is decisions entrant works that advantage out Amgen can full market. on Horizon, our in to go whole hope And chronic, really for data and that we them. be

Michael Higgins

the believe to of mid-XXXX. a start but Makes started And from of the sense. forward we're on follow-up it. THRIVE-X. seeing half the trial lot here Look November, delayed screen in one then I to first

what for feedback and us drove So Thanks. that? any

Scott Myers

Yes.

this late year. you actually THRIVE study that think started, last it's said THRIVE-X started year would and I start actually, So later the THRIVE-X

Deepa Rajagopalan

Mid-year.

Scott Myers

not -- So clear, just be to has THRIVE-X the study yet. not started that's

Kristian Humer

enrollment on providing THRIVE. around not guidance And any we're

Todd James

Hey it's Michael, Todd.

proof-of-concept really data year, middle see in be THRIVE-X the and this chronic second the starting quarter. of when we will On in informed the here that generate the

the execution the And some stakeholder so data, and protocol get thing, just the see study. open that's operational feedback, finalize

to get so actually of in pretty And the in year opened Phase QX the have III and solid that execution. data middle is

slight a just So change there.

Michael Higgins

makes Appreciate lot a Okay. of That Thanks it. sense. guys.

Scott Myers

Thanks, Michael.

Operator

is Needham. [Operator from Serge coming of Belanger Instructions]. question next The

Serge Belanger

Also good welcome, and to us. questions congratulate wanted Scott. Two morning. Hi, for

First just one of ex-U.S. you we question for And week-XX the trial, target site second the think III are on the discuss the proof-of-concept want XXX Phase whether talk should THRIVE And you maybe is, of I you openings? presence you affect terms mentioned me of and in two about enrollment? enrollment, just think just remind any but don't other Thank TEPEZZA where trial? data the to mix you. again, expect cohorts between could the U.S. of

Scott Myers

Yes.

and the a the across couple please? have question, then U.S. we're North XX second opened. smattering clinical Majority and mid-sized out could five, the the sites patients. repeat first in you roll question, Europe and that Europe. are a XXX on America U.K. XX in couple of So big targeting would in And of Currently we the sites countries

Serge Belanger

expect was question week-XX trial? the cohorts should other whether the Second two data we proof-of-concept for of

Deepa Rajagopalan

great question. Yes,

you. the we that make scientific We to We that data those conference analyzing form. a of data, sure Thank and of to want share look we process those data forward that you to sharing bring in a are the and at totality scientific in soon.

Todd James

after doses. is day patients XX additional and remind zero Todd. just day don't I'll everybody that receive this Serge, And dosing

the data being it's look we follow-up really, patients the safety week at aren't when dosed just about gets And the that longer. duration periods, past at longer doses, potential patient two response and six actively that of so time from

further should for zero. be much And so expectations pretty efficacy

Serge Belanger

you. Thank

Scott Myers

you. Thank

Operator

conclusion question-and-answer back Scott session. Myers, the time, would closing the the for to remarks. now I President this call At turn Viridian's like have CEO, and we to of reached over

Scott Myers

Donna, thanks you, everyone Thank this morning. time for your to Great. and

questions, upcoming we any everyone James this have looks you. with spring. team and to out you to if Stone, have reach wonderful forward to are Thanks, Our interacting or day. base happy conferences at to a free Please feel and again, follow-up Louisa with touch Todd

Operator

this gentlemen, conference and call. Ladies concludes today's

You you participating. for may lines. disconnect your Thank

Viridian Therapeutics (VRDN) 8 Mar 232022 Q4 Earnings call transcript